Matrubials GTM brain

Matrubials develops milk-inspired antimicrobial peptides, initially for bacterial vaginosis, with prospective applications for women's health providers and drug partners.

category

Anti-infective therapeutics

market profile

  • text: Bacterial vaginosis is a recurrent dysbiosis with reproductive and infectious complications; the company is pursuing a topical candidate.
  • text: A published preclinical study reports activity against BV-associated pathogens while some peptides spared beneficial lactobacilli; clinical benefit remains unproven.

personas

  • title: OB-GYN or women's health clinician
    pains:
    • Recurrent bacterial vaginosis disrupts patients' lives and can bring reproductive complications.
    • Existing antibiotic approaches can disrupt beneficial vaginal bacteria.
  • title: Women's health pharmaceutical business development lead
    pains:
    • Needs differentiated anti-infective assets with convincing safety and efficacy evidence.
    • Must assess development and regulatory risk before committing to a partnership.

icp

  • text: Potential development partners include pharmaceutical or biotech companies with women's health and anti-infective portfolios; this is an inferred future buyer, not a disclosed customer segment.
  • text: Future clinical adopters could include gynecology practices treating recurrent BV in reproductive-age patients, subject to clinical validation and approval.

message pillars

  • text: Develop therapies inspired by protective milk molecules.
  • text: Focus on selectivity and antimicrobial resistance.
  • text: Apply the platform first to women's health.

objections

  • objection: Is there clinical evidence and regulatory approval?
    response: The cited study is preclinical; request current trial and regulatory status rather than assuming clinical efficacy.
  • objection: Will a new antimicrobial harm beneficial bacteria?
    response: Selectivity is a stated design goal and preclinical findings are encouraging, but human outcomes require validation.

competitors

  • name: Peptilogics
    why: Develops peptide-based anti-infective therapeutics; a broader modality competitor.
  • name: Spero Therapeutics
    why: Develops anti-infective therapies and competes for attention and resources in antimicrobial drug development.

influencers

  • name: Ishita Shah
    url: https://www.ycombinator.com/companies/matrubials-inc
    why: Co-founder and CEO associated with the company's development narrative.

keywords

  • bacterial vaginosis treatment
  • recurrent BV treatment
  • antimicrobial peptides
  • vaginal microbiome therapeutics
  • antibiotic resistance drug development
  • milk derived peptides

voice

  • scientific
  • mission-led
  • accessible

signals

  • text: A pharma company is expanding its women's health or anti-infective pipeline, suggesting potential partnering interest.
  • text: A research or clinical group is studying recurrent BV and preservation of the vaginal microbiome.

pricing

model: unknown

motion

unknown

confidence

medium

Founders

  • name: Bruce German
    title: Founder
    role: Founder
    bio: Bruce is a PhD from Cornell University, Distinguished Professor at the University of California, Davis and director of the Foods for Health Institute. His research focuses on the evolution of lactation and the biological mechanisms by which milk supports the growth, development and performance of infants. He is a co-founder of companies into the therapeutic health space: Evolve Biosystems, BCD Bioscience, Digestiva Inc. and Matrubials.
  • name: Carlito Lebrilla
    title: Founder
    role: Founder
    bio: Dr. Carlito B. Lebrilla is a Distinguished Professor at the University of California, Davis in the Department of Chemistry and Biochemistry and Molecular Medicine in the School of Medicine. His research is in Analytical Chemistry focused on mass spectrometry with applications to clinical glycoproteomic and biofunctional food. He has co-founded startups in Food and Biotechnology including Evolve Biosystems, BCD Bio and InterVenn.
  • name: David Mills
    title: Founder
    role: Founder
    bio: David A. Mills is a Professor in the Department of Food Science & Technology at the UC Davis. Dr. Mills studies the molecular biology and ecology of bacteria that play an active role in gut health or fermented foods. He is the Peter J. Shields Endowed Chair (2012), a Fellow in the American Academy of Microbiology (2015), and has been named a Highly Cited Researcher by Clarivate Analytics since 2018. He is also a co-founder of three start ups; Evolve Biosystems, BCD Bioscience, and Matrubials.

Back to YC companies